December 2026 Options Now Available For Neogen (NEOG)

A covered-call idea on Neogen Corp (NEOG) is described: buy shares at $7.02 and sell the Dec 2026 $7.50 call (current bid $0.10), which yields a total return of 8.26% if assigned at expiration and a 1.42% immediate premium boost (1.44% annualized) if the option expires worthless. The analytics put the odds of the call expiring worthless at 37%; implied volatility on the call is 72% versus a trailing 12‑month volatility of 69%, and the piece highlights the trade-off of capped upside if shares rally materially.

Analysis

Market structure: The covered‑call setup benefits yield‑seeking option sellers and buy‑write income strategies — you lock in an 8.26% gross return to Dec 2026 (stock at $7.02, $7.50 call for $0.10) while ceding upside above $7.50. Liquidity and skew matter: the call bid of $0.10 and implied vol 72% (vs realized ~69%) signal only a small premium edge and potentially wide spreads; options market makers and retail sellers capture most short‑dated income here. Cross‑asset impact is negligible at market level but a sudden agri/food safety shock could reprice credit spreads for related small‑cap suppliers and lift volatility across small‑cap indices.

Risk assessment: Tail risks include a product recall, regulatory action, or major revenue miss that could drop shares >30% (to <$5) quickly, producing assignment/liquidity risk for covered‑call holders. On immediate horizons (days–weeks) execution costs and wide bid/ask dominate P/L; over months the main drivers are earnings, commodity prices, or M&A rumors that can move IV ±20pts. Hidden dependency: low option liquidity makes rolling costly and increases slippage; the 37% quoted odds of expiry worthless imply a 63% chance of finishing ITM per current model — treat that as model‑sensitive, not certainty.

Trade implications: For income investors, a disciplined buy‑write (buy at <=$7.10, sell Dec‑2026 $7.50 for ≥$0.10) is reasonable sized 1–2% portfolio exposure, with a hard 20% stop or protective put if downside >20%. If you prefer to accumulate lower, sell cash‑secured Dec‑2026 puts at strikes ≤$6.00 only if IV ≥60% to earn a better basis; for directional upside buyers avoid covered calls and use either equity or long calls/LEAPs when IV compresses below 60%. Monitor IV‑realized spread: if IV collapses >15 pts within 60 days, unwind and redeploy into higher‑liquidity small‑cap opportunities.

Contrarian angles: The market is not richly pricing premium — IV ~ realized — so the covered‑call “income” is modest and may be undercompensating for assignment risk and illiquidity; consensus underestimates the cost of rolling. Historical parallels (small‑cap buy‑write strategies) show assignment often occurs before bid‑driven spikes, forcing taxable events and reinvestment at higher prices. Unintended consequence: repeated writes on illiquid contracts can compound slippage; prefer specific execution limits, small position sizes, and explicit roll/assignment rules rather than ad hoc selling.

Key Decisions for Investors

• Establish a conservative buy‑write: size 1–2% of portfolio by buying NEOG at ≤$7.10 and selling the Dec‑2026 $7.50 call for ≥$0.10; target gross return 8.26% to expiry, set automatic sell if stock falls 20% (≈$5.62) or buy a protective Dec‑2026 put (strike ≈$6) if put cost ≤$0.60 to cap downside.
• If willing to acquire at a lower basis, sell cash‑secured Dec‑2026 puts at the $6.00 strike (size 1–2%); only execute if implied vol ≥60% and collected premium results in net basis ≤$6.00, otherwise pass due to poor premium pickup.
• Avoid naked calls or large outright long exposure until fundamentals/volume improve; if directional bullish, prefer outright equity (max 0.5–1% portfolio) or buy LEAP calls only when IV falls below 60% or option bid/ask tightens (spread <20% of premium).
• Operational rule: if implied vol compresses by >15 percentage points within 60 days or option bid/ask spread narrows to <20% of mid, close positions and either roll up/out or redeploy proceeds into higher‑liquidity small‑cap names; review before earnings and any regulatory filings within next 90 days.